Journey Medical Corp AI Stock Analysis
Want to see DERM full AI Analyst Report?
Journey Medical Corp (DERM) AI Stock Analysis
Journey Medical Corp
(NASDAQ:DERM)
The score is primarily held back by transitional financial quality (ongoing net losses and negative free cash flow) and weak technicals (price below major moving averages with negative MACD). These risks are partially offset by constructive earnings-call momentum—improving commercial execution, positive EBITDA quarters, and expected payer-access catalysts into 2027—while valuation provides limited support due to negative earnings and no dividend data.
Journey Medical Corp (DERM) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $122.21M
- Dividend Yield
- ―
- Average Volume (3M)
- 183.60K
- Price to Earnings (P/E)
- -23.3
- Beta (1Y)
- 0.59
- Revenue Growth
- 17.03%
- EPS Growth
- 49.40%
- Country
- US
- Employees
- 58
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Journey Medical Corp Business Overview & Revenue Model
Company Description
Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the U...
Journey Medical Corp Earnings Call Summary
The call was predominantly positive, marked by revenue and net product sales growth, improving gross margin, two consecutive quarters of positive EBITDA, strong Emrosi prescription and prescriber expansion, favorable refill trends, compelling clinical data, and expected payer-access improvements. The company still reported a GAAP loss, a lower cash balance, one-time vendor settlement costs, temporary prescription volatility following a copay change, and incomplete formulary coverage, but management characterized these issues as manageable or nonrecurring while emphasizing continued commercial momentum.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management expects Emrosi’s key metrics to “continue to trend positively in the coming quarters,” ASP to “trend higher in the coming quarters,” and high-quality coverage to increase from “40% of commercial lives,” or about “170 million, 180 million lives,” after a large national plan covering “over 25 million lives” takes effect at the beginning of 2027; quality coverage means “a single-step or better.” Management expects the plan’s impact to be felt “beginning in Q1,” anticipates an “upward trend on ASP and improvement in gross-to-net as the quarters progress in '27,” expects newly added representatives to have “a good 2 quarters” to become productive, and said prescription volatility after the copay change might take “anywhere from 4 to 8 weeks” to recover. SG&A is expected to be “consistent or a little bit lower as a percentage of revenue,” while management is “probably going to be somewhat apprehensive here in the first half of next year to give any particular guidance” on 2027 revenue or EBITDA.
Journey Medical Corp Financial Statement Overview
Summary
Financials show a rebound with very strong TTM revenue growth and improving profitability (EBITDA turning positive), and leverage appears manageable. However, the company is still reporting net losses and the cash flow profile is the key weakness, with TTM operating cash flow and free cash flow remaining negative.
Income Statement
44NeutralBalance Sheet
56NeutralCash Flow
32Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 69.52M | 61.86M | 56.13M | 79.18M | 73.67M | 63.13M |
| Gross Profit | 30.03M | 36.68M | 35.26M | 52.52M | 42.89M | 31.05M |
| EBITDA | 2.74M | -3.33M | -8.40M | 1.92M | -23.18M | -32.77M |
| Net Income | -5.10M | -11.43M | -14.67M | -3.85M | -29.63M | -43.99M |
Balance Sheet | ||||||
| Total Assets | 103.85M | 94.59M | 80.24M | 76.85M | 105.16M | 97.28M |
| Cash, Cash Equivalents and Short-Term Investments | 22.32M | 24.09M | 20.30M | 27.44M | 32.00M | 49.08M |
| Total Debt | 25.62M | 25.40M | 25.70M | 17.73M | 22.96M | 9.05M |
| Total Liabilities | 71.60M | 62.74M | 60.17M | 56.50M | 88.18M | 55.24M |
| Stockholders Equity | 32.25M | 31.85M | 20.07M | 20.35M | 16.98M | 42.04M |
Cash Flow | ||||||
| Free Cash Flow | -8.55M | -12.44M | -24.13M | 240.00K | -33.53M | -12.18M |
| Operating Cash Flow | -8.55M | -12.44M | -9.13M | 5.24M | -13.53M | -2.18M |
| Investing Cash Flow | 0 | 0 | -15.00M | -5.00M | -20.00M | -10.00M |
| Financing Cash Flow | 5.92M | 16.23M | 16.99M | -4.80M | 16.46M | 53.02M |
Journey Medical Corp Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DERM, the sentiment is Negative. The current price of 4.33 is below the 20-day moving average (MA) of 4.80, below the 50-day MA of 5.89, and below the 200-day MA of 6.44, indicating a bearish trend. The MACD of -0.42 indicates Negative momentum. The RSI at 33.33 is Neutral, neither overbought nor oversold. The STOCH value of 21.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DERM.
Journey Medical Corp Risk Analysis
Journey Medical Corp disclosed 62 risk factors in its most recent earnings report. Journey Medical Corp reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksJourney Medical Corp Peers Comparison
Overall Rating
TKNO56Neutral
CPIX53Neutral
TLPH49Neutral
DERM47Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 56Neutral | $516.43M | -27.83 | -24.95% | ― | 15.45% | 12.64% | |
| 53Neutral | $88.10M | 1.28 | 202.58% | 23.57% | -39.11% | -241.27% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | $47.07M | -3.50 | -96.70% | ― | -100.00% | 46.24% | |
| 47Neutral | $122.21M | -23.29 | -16.07% | ― | 17.03% | 49.40% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DERM | Journey Medical Corporation | 4.33 | -3.62 | -45.53% | |
| TLPH | Talphera, Inc. | 0.91 | -0.43 | -32.39% | |
| CPIX | Cumberland Pharmaceuticals Inc. | 5.88 | 4.35 | 285.07% | |
| SXTC | China Sxt Pharmaceuticals | 3.00 | -1919997.00 | -100.00% | |
| TKNO | Alpha Teknova, Inc. | 8.21 | 3.80 | 86.17% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026
